Retatrutide, a triple-agonist (GLP-1, GIP and glucagon), is in late-stage trials and has produced even more weight loss in early data up to 24% at 48 weeks in phase 2
Some researchers explore complementary approaches to support weight maintenance during and after GLP-1 agonist use
Add Ashwagandha powder, turmeric, cinnamon, and ginger to the saucepan
A perfectly chosen site, used repeatedly in the same spot, can become less effective than a rotated thigh site
Looking ahead, enrolling in a Part D plan that participates in BALANCE will be important for continued access beyond that
Factors such as dosage, duration of use, weight loss, and metabolic changes can all contribute to the diversity of responses